Gemcitabine

Gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer

#ESMO21 Highlights on gemcitabine vs mFOLFIRINOX in resected pancreatic cancer: PRODIGE 24/CCTG PA6

European Society for Medical Oncology (ESMO)

Schedules for Gemcitabine, Nab-Paclitaxel for Pancreatic Cancer

Gemcitabine

The Ruesch Center

A promising future for gemcitabine-oxaliplatin in cisplatin-unfit advanced urothelial carcinoma

Gemcitabine, cisplatin, and nab-paclitaxel in advanced biliary tract cancers

KEYNOTE-966: pembrolizumab, gemcitabine and cisplatin for CCA

Dosing Options With Nab-Paclitaxel/Gemcitabine

Dr. Simeone on Benefit of Neoadjuvant Gemcitabine in Pancreatic Cancer

Pancreatic cancer properties describe gemcitabine response

Journal of Clinical Investigation

Gemcitabine and Complementary Treatments for Cancer

Immunotherapy Institute

Gemcitabine

Curie Oncology SG

Dr. Gupta on the Use of Enzalutamide, Gemcitabine, and Cisplatin in Metastatic Bladder Cancer

SEQUENCE: nab-paclitaxel/gemcitabine with modified FOLFOX in pancreatic cancer

Debate: Optimal adjuvant chemotherapy for resected pancreatic cancer - Gemcitabine/capecitabine

The protein RRP9 promotes gemcitabine resistance in pancreatic cancer by activating the AKT pathway

AJE Video Bytes

Dr. O'Reilly on Nab-Paclitaxel Plus Gemcitabine Vs FOLFIRINOX

NEPAFOX: adjuvant gemcitabine vs. FOLFIRINOX in resectable pancreatic cancer

Chemotherapy for Pancreatic Cancer: Gemcitabine + Abraxane

The Ruesch Center

GI Chemotherapy Education – GA/GemNab: Gemcitabine and Nab-paclitaxel (Abraxane®)

MD Anderson Cancer Center